Printed from Voxsanity (voxsanity.com.au) — NCT07728669 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Type 2 Diabetes
Type 2 Diabetes Trial, Recruiting
NCT07728669
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged 21 to 65 years old at the time of signing the consent form.
- People of any sex (male or female).
- People who are overweight and also have at least one related health condition, such as type 2 diabetes, high blood pressure, abnormal cholesterol or triglyceride levels, heart disease, breathing or joint problems, fatty liver disease, sleep problems, or another related condition.
- People who are overweight (not yet in an obesity category) with a body mass index (BMI) in the range of 25.0–29.9 for Caucasian populations or 23.0–27.4 for Asian populations, and who also have excess weight around the waist (waist measurement of at least 94 cm for men or 80 cm for women in European populations, or at least 90 cm for men or 80 cm for women in Asian populations).
- People with Class I, II, or III obesity whose attempts to lose weight through diet and exercise have not resulted in at least 5% weight loss over 3 months.
- People with Class I obesity, defined as a BMI of 30.0–34.9 for Caucasian populations or 27.5–32.4 for Asian populations.
- People with Class II obesity, defined as a BMI of 35.0–39.9 for Caucasian populations or 32.5–37.4 for Asian populations.
- People with type 2 diabetes confirmed by specific blood sugar measurements (confirm with trial site for the exact values that apply).
- People with a BMI between 25 and 40 at the time of their screening appointment.
- People who have already been independently prescribed the medication semaglutide (a GLP-1 receptor agonist) by their own treating doctor, separate from and unrelated to this study — the study does not prescribe or change this medication.
- People who have been on stable doses of any ongoing medications (such as blood pressure or cholesterol medications) for at least 8 weeks before screening.
- People who own an iOS or Android smartphone with internet access and are willing to download and use an app called "NutriSteppe" if assigned to the group that uses it.
- People who are able and willing to give written consent and follow the study procedures.
- Women who could become pregnant must agree to use effective contraception throughout the study.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People with a diagnosis of type 1 diabetes.
- People with a history of diabetic ketoacidosis or a severe high-blood-sugar emergency called hyperglycemic hyperosmolar state.
- People who started semaglutide treatment less than 4 weeks before their screening appointment.
- People currently using insulin therapy.
- People with a personal or family history of a specific type of thyroid cancer called medullary thyroid carcinoma.
- People with a personal history of a condition called Multiple Endocrine Neoplasia type 2 (MEN2).
- People with a history of inflammation of the pancreas (pancreatitis), whether past or ongoing.
- People with active gallbladder disease or a history of gallbladder disease within the 6 months before screening.
- People with serious digestive conditions, including a condition where the stomach empties too slowly (gastroparesis).
- People who have had a major heart or stroke event within the 6 months before screening, such as a heart attack, stroke, mini-stroke, unstable chest pain, or heart bypass or stent procedures.
- People with poorly controlled high blood pressure (systolic above 160 mmHg or diastolic above 100 mmHg) at screening.
- People with significantly reduced kidney function, as measured by a specific blood test result below a set threshold (confirm with trial site).
- People with severe liver disease classified at a specific severity level, or with liver enzyme levels more than three times the normal upper limit.
- People with an active cancer diagnosis or a history of cancer within the past 5 years, except for certain successfully treated skin cancers (basal cell or squamous cell carcinoma).
- People with HIV, active hepatitis B (confirmed by specific blood markers), or hepatitis C infection.
- People who have had weight-loss (bariatric) surgery in the past, or who plan to have it during the study.
- People with an active or recently diagnosed (within the past year) eating disorder, including anorexia nervosa, bulimia nervosa, or binge eating disorder.
- People who are pregnant or breastfeeding.
- People who are planning to become pregnant during the study period.
- Women who could become pregnant but are unwilling to use effective contraception.
- People who have used weight-loss medications (such as orlistat, phentermine, or similar drugs) within 3 months before screening.
- People who have used oral or injected corticosteroid medications (not inhaled or topical) for more than 2 weeks in the 3 months before screening.
- People taking antipsychotic medications known to cause significant weight gain, unless they have been on a stable dose for more than 6 months.
- People who have participated in another interventional clinical trial within 30 days before screening.
- People with a known allergy or sensitivity to semaglutide or any of its ingredients.
- People who do not own a smartphone or are unwilling to use digital health technology.
- People with a severe mental health condition that would prevent them from giving informed consent or following the study procedures.
- People with active alcohol or drug dependence within the past year.
- People with any other condition that the study investigator believes could affect participant safety or the reliability of the study results.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
Contact this trial
Principal Investigator: Almaz Sharman, MD, PhD, Kazakh Academy of Nutrition LLP
Phone: +77757211170
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Not Applicable
Sponsor
Kazakh Academy of Nutrition
Registry
ClinicalTrials.gov
Start date
20 July 2026
Est. completion
1 November 2026
Where this trial is recruiting
🇰🇿 Kazakhstan
Primary endpoints
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.